A bovine lipocalin, previously identified as a putative odorant-binding protein in bovine colostrum (bcOBP), was cloned and expressed, and its monoclonal antibody was established. bcOBP was constantly secreted into milk on day of parturition until at least 10 d postpartum at a concentration of 181±39 µg/L. Besides milk, bcOBP occurred in the nasal mucus, saliva, amniotic fluid, vaginal discharge, and blood plasma. Despite its low concentration, the distribution pattern and the finding that bcOBP harbored a characteristic sequence motif, CxxxC, which is conserved among insect and mammal pheromone binding proteins, suggest that bcOBP functions as a pheromone carrier. The presence of bcOBP in the plasma at varied concentrations depending on the lactation period does not exclude the possibility that bcOBP is secreted into milk from the blood. Cross-reactivity of the monoclonal antibody indicated presence of proteins homologous to bcOBP in the colostrum of farm animals of Cetartiodactyla.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1271/bbb.110840 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Uptake of rituximab biosimilars in Medicare and Medicaid in 2019-2022.
Am J Manag Care
December 2024
Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, 4306D Walker Building, Auburn University, Auburn, AL 36849-5506. Email:
Objectives: This study evaluated the uptake and costs of 3 biosimilars among Medicare and Medicaid populations for 2019 to 2022: rituximab-abbs (Truxima), rituximab-pvvr (Ruxience), and rituximab-arrx (Riabni).
Study Design: A retrospective, descriptive study.
Methods: Using the annually aggregated, product-level utilization and cost data of biologic and biosimilar rituximab products from CMS drug spending data, total claims and costs (reimbursement and out of pocket) for all rituximab products were identified and extracted from Medicare Part B, Medicare Part D, and Medicaid.
Assembly and performance of a cholera RDT prototype that detects both and associated bacteriophage as a proxy for pathogen detection.
J Clin Microbiol
December 2024
Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
Cholera rapid diagnostic tests (RDTs) are vulnerable to virulent bacteriophage predation. We hypothesized that an enhanced cholera RDT that detects the common virulent bacteriophage ICP1 might serve as a proxy for pathogen detection. We previously developed a monoclonal antibody (mAb) to the ICP1 major capsid protein.
View Article and Find Full Text PDFVirus Protein-Specific Immune Responses in Selective Depletion of Lymphocyte Populations Using Monoclonal Antibodies in Bolivian Squirrel Monkeys ().
Viral Immunol
January 2025
Department of Comparative Medicine, The University of Texas MD Anderson Cancer Center, Bastrop, Texas, USA.
The increasing use of immune suppressive monoclonal antibodies in the treatment of organ transplant recipients and patients with oncologic, neurological, and autoimmune diseases can lead to serious morbidity and mortality from the reactivation of viral agents that persist in humans. The squirrel monkey polyomaviruses are naturally found in Bolivian squirrel monkeys (SQM) and may be a useful model for the study of polyomavirus-associated pathogenesis and experimental treatment and prevention strategies. Two diverse groups of squirrel monkeys were given, a single dose of an anti-B cell antibody (rituximab) resulting in complete depletion of B cells (CD20+), while an anti-CD8 monoclonal antibody (7 pt-3F9) resulted in a transient depletion of CD8+ lymphocytes compared with control animals (group with no infusion with either of the monoclonal antibodies).
View Article and Find Full Text PDFA Surrogate BSL2-compliant Infection Model Recapitulating Key Aspects of Human Marburg Virus Disease.
Emerg Microbes Infect
January 2025
State Key Laboratory of Pathogenic Microorganisms, Key Laboratory of Jilin Province for Zoonosis Prevention and Control, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Marburg virus disease (MVD) is a severe infectious disease characterized by fever and profound hemorrhage caused by the Marburg virus (MARV), with a mortality rate reaching 90%, posing a significant threat to humans. MARV lies in its classification as a biosafety level four (BSL-4) pathogen, which demands stringent experimental conditions and substantial funding. Therefore, accessible and practical animal models are urgently needed to advance prophylactic and therapeutic strategies for MARV.
View Article and Find Full Text PDFSubcutaneous Administration of Therapeutic Monoclonal Antibody Drug Products Using a Syringe in Blinded Clinical Trials: Advances and Key Aspects Related to Blinding/Matching/Masking Strategies for Placebo Formulation.
Mol Pharm
January 2025
Drug Product Development-Steriles, Medicine Development and Supply, GSK, 1250 S. Collegeville Road, Collegeville, Pennsylvania 19426, United States.
Therapeutic monoclonal antibody (mAb) drug products are increasingly used to treat both chronic and acute diseases. These mAb drug products are often developed for subcutaneous (SC) injection to simplify dosing compared with intravenous (IV) infusion. For SC injection, the mAb liquid drug product is typically filled in a vial for use with a syringe or in a prefilled syringe, which can then be assembled into a safety syringe device or an autoinjector for direct administration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!